SCL-1
Based on 1 Customer Validation
SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and natural killer cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.63%
- CAS No.: 1061105-16-5
- 화학식: C18H23F3N6O
- 분자량:396.41
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
SCL-1 (0.25-100 μM, 4 days) has no significant cytotoxicity in MDA-MB231 cell[1].
SCL-1 (25 μM) inhibits exhibits moderate inhibitory activities against PD-1/PD-L1 binding with inhibition rate of 63%[2].
SCL-1 inhibits SCC3 and Jurkat cell proliferation with IC50 values >50 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | T1/2 | Tmax | Cmax |
|---|---|---|---|---|---|
| Mice[1] | 100 mg/kg | p.o. | 1.75 h | 0.5 h | 4.63 μg/mL |
SCL-1 (50 mg/kg, p.o., 10 times over 14 days) suppresses tumor growth in humanized SCC-3 tumor-bearing MHC-dKO NOG mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB231 tumor in a humanized MHC-double knockout NOG mice models[1]
-
Dosage:25, 50 and 100 mg/kg
-
Administration:Orally administered, 10 times over 14 days (days 1-5 and 8-12)
-
Result:Inhibited tumor volume.
Did not induce weight loss.
Increased infiltrated CD4+ and CD8+ T-cell numbers inside tumors.
Increased the frequency of CD19+ B cells that infiltrated tumors.
Showed high level of lymphoid cell infiltration.
Upregulated T cell-associated cytotoxic genes (GZMB, PRF1, and IFNB1), exhausted marker genes (PD-1, TIM3, and CD39), NK activation-associated genes (CD16 and NCR1), and T-cell attracting chemokine genes (CCL3 and CCL4).
Downregulated CXCL12 gene expression.
Upregulated tumor-specific long non-coding (lnc) RNAs.
-
Animal Model:Humanized SCC-3 tumor-bearing MHC-dKO NOG mice[2]
-
Dosage:50 mg/kg
-
Administration:Orally administered, 10 times over 14 days (days 1-5 and 8-12)
-
Result:Promoted the engraftment of transplanted human PBMCs in the spleens.
Increased the number of infiltrated CD45+ human PBMCs and CD4+ and CD8+ T cells inside the tumors.
Had more foci of lymphoid cell infiltration with necrotic changes.
Increased CD8+ T cells.
Upregulated the expression of CXCL9 and CXCR3.
Downregulated the expression levels of CCL22 and TIM3.
Chemical Information
-
CAS No. 1061105-16-5
-
Appearance Solid
-
분자량 396.41
-
화학식 C18H23F3N6O
-
Color White to off-white
-
SMILES
CC1CCCCN1C(C2CCN(CC2)C3=NN4C(C=C3)=NN=C4C(F)(F)F)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
용액&용해도
DMSO : 100 mg/mL (252.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ikeya T, et al. Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model. Sci Rep. 2025 Jul 24;15(1):26918. [Content Brief]
[2]. Akiyama Y, et al. Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer Res. 2022 Nov;42(11):5233-5247. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5226 mL | 12.6132 mL | 25.2264 mL | 63.0660 mL |
| 5 mM | 0.5045 mL | 2.5226 mL | 5.0453 mL | 12.6132 mL | |
| 10 mM | 0.2523 mL | 1.2613 mL | 2.5226 mL | 6.3066 mL | |
| 15 mM | 0.1682 mL | 0.8409 mL | 1.6818 mL | 4.2044 mL | |
| 20 mM | 0.1261 mL | 0.6307 mL | 1.2613 mL | 3.1533 mL | |
| 25 mM | 0.1009 mL | 0.5045 mL | 1.0091 mL | 2.5226 mL | |
| 30 mM | 0.0841 mL | 0.4204 mL | 0.8409 mL | 2.1022 mL | |
| 40 mM | 0.0631 mL | 0.3153 mL | 0.6307 mL | 1.5767 mL | |
| 50 mM | 0.0505 mL | 0.2523 mL | 0.5045 mL | 1.2613 mL | |
| 60 mM | 0.0420 mL | 0.2102 mL | 0.4204 mL | 1.0511 mL | |
| 80 mM | 0.0315 mL | 0.1577 mL | 0.3153 mL | 0.7883 mL | |
| 100 mM | 0.0252 mL | 0.1261 mL | 0.2523 mL | 0.6307 mL |
SCL-1 Related Classifications
HY-175604 Related Classifications
Powered by Bioz